<ENAMEX TYPE="ORGANIZATION">Ciba Geigy Ltd</ENAMEX> and <ENAMEX TYPE="ORGANIZATION">Chiron Corp</ENAMEX> said they extended their offer for <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> Biosciences <ENAMEX TYPE="ORGANIZATION">Inc</ENAMEX> valued at 866 million Canadian dollars US 736 million to Oct 27 The companies earlier said they didn t want to raise their offer to match a rival bid by <ENAMEX TYPE="ORGANIZATION">Institut Merieux S A</ENAMEX> of <ENAMEX TYPE="LOCATION">C</ENAMEX> 37 <ENAMEX TYPE="ORGANIZATION">NNP</ENAMEX> a share or C 942 million But they said the <ENAMEX TYPE="LOCATION">C</ENAMEX> 30 a share bid which was due to expire Monday may still be extended or varied <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> a vaccine manufacturer based in <ENAMEX TYPE="LOCATION">Lyon France</ENAMEX> is 51 held by French state owned <ENAMEX TYPE="ORGANIZATION">Rhone Poulenc S A Ciba Geigy</ENAMEX> is a major pharmaceutical concern based in <ENAMEX TYPE="LOCATION">Basel Switzerland Chiron</ENAMEX> another pharmaceutical concern is based in <ENAMEX TYPE="ORGANIZATION">Emeryville Calif Connaught</ENAMEX> is a biotechnology research and vaccine manufacturing concern <ENAMEX TYPE="ORGANIZATION">Institut Merieux</ENAMEX> s bid for <ENAMEX TYPE="LOCATION">Toronto</ENAMEX> based <ENAMEX TYPE="ORGANIZATION">Connaught</ENAMEX> has run into problems with the Canadian government which told <ENAMEX TYPE="ORGANIZATION">Merieux</ENAMEX> last week that it wasn t convinced that the proposed acquisition would be of net benefit to <ENAMEX TYPE="LOCATION">Canada Merieux</ENAMEX> officials are expected to meet with federal officials in <ENAMEX TYPE="LOCATION">Ottawa</ENAMEX> today to discuss the decision